Related Experiment Video
Updated: Jun 22, 2026
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
[Effect of pentoxifylline on the evolution of diabetic nephropathy]
Rafael Leyva-Jiménez1, Alaín R Rodríguez-Orozco, Luz Elena Ortega-Pierres
1Unidad de Investigación en Epidemiología Clínica, Hospital General Regional No. 1 (HGR No. 1), Instituto Mexicano de Seguro Social (IMSS). Morelia, Michoacán, México.
Background And Objective:
Diabetic nephropathy (DN) is the principal cause of end-chronic kidney disease. Metabolic and hemodynamic components are directly involved. However, convincing data have shown that inflammation participates in the diabetic complications. The aim of this study was to investigate whether the inhibition of the inflammation and pro-inflammatory cytokines with pentoxifylline (PXF) attenuate the progression of the DN.
Subjects And Method:
In a prospective, randomized, double-blind, placebo- controlled study, we evaluated the effect of PXF (1200 mg daily) during 12 months, in 34 patients with incipient or established DN. Evaluated parameters were inflammation, pro-inflammatory cytokines and urinary albumin excretion (UAE).
Results:
PXF treatment had a reno-protective effect determined by a significant reduction in the UAE in both incipient and established (p<0,01) DN patient. This effect was attributed to a reduction in the C-reactive protein, interleukin-6, tumor necrosis factor-alpha and leptin serum levels (p<0,01).
Conclusions:
PXF treatment caused regression and prevented the progression of renal damage. Thus, PXF should be used in the preventive treatment of DN. These results showed that inflammation and pro-inflammatory cytokines are related to the progression of diabetic nephropathy.
Insights
Pentoxifylline (PXF) reduces inflammation and pro-inflammatory cytokines, significantly decreasing urinary albumin excretion in diabetic nephropathy patients. This treatment offers a renoprotective effect, preventing further kidney damage progression.
Area of Science:
- Nephrology
- Endocrinology
- Immunology
Context:
- Diabetic nephropathy (DN) is a leading cause of end-stage renal disease.
- Inflammation and pro-inflammatory cytokines play a significant role in DN progression.
- Current treatments for DN have limitations in addressing inflammatory pathways.
Purpose:
- To investigate the efficacy of pentoxifylline (PXF) in inhibiting inflammation and pro-inflammatory cytokines.
- To determine if PXF attenuates the progression of diabetic nephropathy.
- To evaluate the impact of PXF on urinary albumin excretion (UAE) and inflammatory markers.
Summary:
- A 12-month prospective, randomized, double-blind, placebo-controlled study involving 34 DN patients evaluated PXF (1200 mg daily).
- PXF treatment significantly reduced UAE in both incipient and established DN.
- Reductions in C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and leptin serum levels were observed.
Impact:
- PXF demonstrated a renoprotective effect, reducing and preventing renal damage progression in DN patients.
- The findings suggest that inflammation and pro-inflammatory cytokines are key drivers of DN progression.
- PXF emerges as a potential therapeutic agent for the preventive treatment of diabetic nephropathy.
Related Concept Videos
01:28Diabetic Nephropathy
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions